Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004166 | 0.91 | HSD11B1 (0.35) | PARP1HSD11B1 | |
| SCHEMBL7001564 | 0.89 | HTR1A (0.35) | PARP1HTR1A | |
| SCHEMBL7007832 | 0.82 | MTNR1A (0.38) | — | |
| SCHEMBL958204 | 0.76 | CHRM2 (0.35) | PARP1 | |
| SCHEMBL625416 | 0.76 | CHRM2 (0.35) | PARP1 | |
| SCHEMBL211419 | 0.76 | CHRM2 (0.35) | PARP1 | |
| SCHEMBL7005115 | 0.72 | ACE (0.41) | — | |
| SCHEMBL30681463 | 0.71 | SCN9A (0.40) | — | |
| SCHEMBL30681436 | 0.71 | SCN9A (0.40) | — | |
| SCHEMBL30681288 | 0.69 | NOTUM (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1288216-A1 | TRICYCLIC QUINAZOLINEDIONES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105118-A1 | Tricyclic quinazolinediones | PARP1, PARP11, PARP2 | PARP1 1/4885HSD11B1 1000/4885HTR1A 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.